SMARCA4缺失的非小细胞肺癌1例
One Case of Non-Small Cell Lung Cancer with SMARCA4 Deletion Was Reported
DOI: 10.12677/md.2024.141020, PDF,   
作者: 宋允龙：济宁医学院临床学院，山东 济宁；张楠楠, 武 薇*：济宁医学院附属医院呼吸与危重症医学科，山东 济宁；袁传涛：济宁医学院附属医院病理科，山东 济宁
关键词: SMARCA4；非小细胞肺癌；SWI/SNF；肺部肿瘤；SMARCA4； Non-Small Cell Lung Cancer； SWI/SNF； Lung Tumors
摘要: SMARCA4缺失型非小细胞肺癌(SMARCA4-deficient non-small cell lung cancer, SMARCA4-Dnsclc)是一类与SWI/SNF复合物突变相关的罕见恶性肿瘤，其临床表现为高度侵袭性，患者预后往往较差，SMARCA4-dNSCLC的主要难点在诊断及治疗方面，本文对一例SMARCA4-dSNCLC患者的临床诊断进行报道，并系统性回顾SMARCA4-dNSCLC的临床表现、病理学、免疫组化及治疗方面的相关研究。
Abstract: SMARCA4-deficient non-small cell lung cancer (SMARCA4 SMARCA4-dNSCLC) is a rare malignancy associated with SWI/SNF complex mutations, which is highly aggressive in clinical manifestations and often has a poor prognosis for patients SMARCA4. This article reports the clinical diagnosis of a patient with SMARCA4-dSNCLC, and systematically reviews the clinical manifestations, pathology, immunohistochemistry and treatment of SMARCA4-dNSCLC.
文章引用：宋允龙, 张楠楠, 袁传涛, 武薇. SMARCA4缺失的非小细胞肺癌1例[J]. 医学诊断, 2024, 14(1): 137-141. https://doi.org/10.12677/md.2024.141020

参考文献

[1] Hen, Z, Fillmore, C.M., Hammerman, P.S., Kim, C.F. and Wong, K.K. (2014) Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases. Nature Reviews Cancer, 14, 535-546. [Google Scholar] [CrossRef] [PubMed]
[2] Nambirajan, A., Singh, V.A., Bhardwaj, N., et al. (2021) SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature. Archives of Pathology & Laboratory Medicine, 145, 90-98. [Google Scholar] [CrossRef] 
[3] Wong, A.K., et al. (2000) BRG1, A Component of the SWI-SNF Complex, Is Mutated in Multiple Human Tumor Cell Lines. Cancer Research, 60, 6171-6177.
[4] Le Loarer, F., Watson, S., Pierron, G., De Montpreville, V.T., et al. (2015) SMARCA4 Inactivation Defines A Group of Undifferentiated Thoracic Malignancies Transcriptionally Related To BAF-Deficient Sarcomas. Nature Genetics, 47, 1200-1205. [Google Scholar] [CrossRef] [PubMed]
[5] 陈雪松, 陈玲, 何梦钰. SMARCA4突变的非小细胞肺癌患者临床特征及相关生物信息分析[J]. 南京医科大学学报(自然科学版), 2023, 43(11): 1520-1526.
[6] 华人民共和国国家卫生健康委员会. 原发性肺癌诊疗指南(2022年版) [J]. 中国合理用药探索, 2022, 19(9): 1-28.
[7] 林华, 李纪宾, 薛丽燕, 等. 16476例肺癌患者病理分型和诊断分期的构成和变化分析[J]. 中国临床医生杂志, 2023, 51(7): 789-793.
[8] 中国临床肿瘤学会血管靶向治疗专家委员会, 中国临床肿瘤学会非小细胞肺癌专家委员会, 中国临床肿瘤学会非小细胞肺癌抗血管生成药物治疗专家组. 晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版) [J]. 中华肿瘤杂志, 2020, 42(12): 1063-1077.
[9] 陈沁阳, 张杰, 谢晓慧, 等. SMARCA4/BRG1缺陷型非小细胞肺 癌的临床病理特点和治疗策略[J]. 中国肿瘤临床, 2022, 49(3): 155-158. [Google Scholar] [CrossRef] 
[10] Muchardt, C.A., and Yaniv, M. (1999) The Mammalian SWI/SNF Complex and the Control of Cell Growth. Seminars in Cell & Developmental Biology, 10, 189-195. [Google Scholar] [CrossRef] [PubMed]
[11] Kadoch, C., et al. (2013) Proteomic and Bioinformatic Analysis of Mammalian SWI/SNF Complexes Identifies Extensive Roles in Human Malignancy. Nature Genetics, 45, 592-601. [Google Scholar] [CrossRef] [PubMed]
[12] Centore, R.C., Sandoval, G.J., Soares, L.M.M., Kadoch, C. and Chan, H.M. (2020) Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies. Trend in Genetics, 36, 936-950. [Google Scholar] [CrossRef] [PubMed]
[13] Agaimy, A., Fuchs, F., Moskalev, E.A., et al. (2017) SMARCA4-Deficient Pulmonary Adenocarcinoma: Clinicopathological, Immunohistochemical, and Molecular Characteristics of a Novel Aggressive Neoplasm with a Consistent TTF1neg/CK7pos/Heppar-1pos Immunopheno Type. Virchows Archiv, 471, 599-609. [Google Scholar] [CrossRef] [PubMed]
[14] Naito, T., Udagawa, H., Umemura, S., Sakai, T., Zenke, Y., Kirita, K., Matsumoto, S., Yoh, K., Niho, S., Tsuboi, M., et al. (2019) Non-Small Cell Lung Cancer with Loss of Expression of the SWI/SNF Complex Is Associated with Aggressive Clinicopathological Features, PD-L1-Positive Status, and High Tumor Mutation Burden. Lung Cancer, 138, 35-42. [Google Scholar] [CrossRef] [PubMed]
[15] 赵艳, 练亿香, 朱德茂, 等. SMARCA4缺失的非小细胞肺癌的临床病理特征[J]. 临床与病理杂志, 2023, 43(5): 873-879.
[16] Armon, S., et al. (2021) Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients. Cells, 10, 1920. [Google Scholar] [CrossRef] [PubMed]
[17] Sesboue, C. and Leloarer F. (2021) SWI/SNF-Deficient Thoraco-Pulmonary Neoplasms. Seminars in Diagnostic Pathology, 38, 183-194. [Google Scholar] [CrossRef] [PubMed]
[18] Schoenfeld, A.J., Bandlamudi, C., Lavery, J.A., et al. (2020) The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 26, 5701-5708. [Google Scholar] [CrossRef] 
[19] Gandhi, J.S., Alnoor, F., Sadiq, Q., et al. (2021) SMARCA4 (BRG1) and SMARCB1 (INI1) Expression in TTF-1 Negative Neuroendocrine Carcinomas Including Merkel Cell Carcinoma. Pathology-Research and Practice, 219, 153341. [Google Scholar] [CrossRef] [PubMed]
[20] Mehta, A., Diwan, H., Bansal, D., et al. (2022) TTF1-Positive SMARCA4/ BRG1 Deficient Lung Adenocarcinoma. Journal of Pathology and Translational Medicine, 56, 53-56. [Google Scholar] [CrossRef] [PubMed]
[21] Bell, E.H., Chakraborty, A.R., Mo, X., et al. (2016) SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer. Clinical Cancer Research, 22, 2396-2404. [Google Scholar] [CrossRef] 
[22] 王新娟, 屠蒙, 贾红霞, 等. PD-1单抗联合化疗与化疗治疗Ⅲ-Ⅳ期SMARCA4缺失型非小细胞肺癌的疗效评估及预后分析[J]. 中国肺癌杂志, 2023, 26(9): 659-668.
[23] Decroix, E., et al. (2020) Les Tumeurs Thoraciques SMARCA4 DÉFicientes: Une Nouvelle Entité. [SMARCA4-De-ficient Thoracic Tumors: A New Entity]. Bulletin Du Cancer, 107, 41-47. [Google Scholar] [CrossRef] [PubMed]
[24] Knutson, S.K., Warholic, N.M., Wigle, T.J., et al. (2013) Durable Tumor Regression in Genetically Altered Malignant Rhabdoid Tumors by Inhibition of Methyltransferase EZH2. Proceedings of the National Academy of Sciences of the United States of America, 110, 7922-7927. [Google Scholar] [CrossRef] [PubMed]